|

| 产地 | 中国 |
| 品牌 | Chemstan |
| 货号 | CSD00214 |
| 保存条件 | store at -80℃ |
| 用途 | 仅用于科研用途 |
| 应用范围 | |
| 抗原来源 | CHO cells |
| CAS编号 | |
| 保质期 | 一年 |
| 抗体名 | Enlimomab Pegol ( 培戈赖莫单抗 ) |
| 是否单克隆 | |
| 克隆性 | |
| 靶点 | ICAM1/CD54[Homo sapiens] |
| 适应物种 | |
| 形态 | |
| 宿主 | |
| 标记物 | |
| 包装规格 | 100μg |
| 纯度 | % |
| 亚型 | |
| 标识物 | |
| 浓度 | 95% |
| 免疫原 | |
| 是否进口 | 否 |
CSD00214
通用名INN
Enlimomab Pegol
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
靶点;物种(Specificity target name;species)
ICAM1/CD54[Homo sapiens]
活性研究(体外/体内研究)(Activity in vitro)
ICAM-1-IN-1 shows significant efficacy in a rat rheumatoid arthritis model and in a mouse asthma model. ICAM-1-IN-1 reduces the width of inflamed ankles after the ninth day following treatment, but shows no efficacy in the acute phase. Treatment with ICAM-1-IN-1 (25 mg/kg) for 21 days significantly reduces the ankle inflammation of the arthritis rats. Significant reduction of eosinophils and serum-soluble ICAM-1 (sICAM-1) is observed.
种类(Species)
Mus musculus
受体鉴定(Receptor identification)
Fab'-G2a-nd